Why UFPT rose on Nov 4
Up 18% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and medical device stocks a median 7%.
“MedTech sales grew 12.5%, reflecting broad-based demand across our portfolio.”
UFPT's Quality Score fell 3 points on Fri, Nov 20, to 5. Its price fell under its average of 8 days (3 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 18% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and medical device stocks a median 7%.
“MedTech sales grew 12.5%, reflecting broad-based demand across our portfolio.”
| The company | Profit up 14% to $77M |
| Latest filing | 10-Q, Nov 6 |
After its last 4 reports it closed +13.2% on average, higher 3 of 4 times.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
UFPT is #30 of 86 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 30 |
Net income over four quarters: UFPT $76.5M, GMED $558M, MMSI $160M, PEN $157M.
Expected to report Tue Feb 23, after the close (in 94 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $172.4M, 12% more than a year ago; a profit of $2.64 a share, from $2.11.
“MedTech sales grew 12.5%, reflecting broad-based demand across our portfolio.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $169M | $173M | $152M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 6)
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +9.3% | +17.7% | +12.0% |
| Aug 3, 2026 | +14.0% | +25.2% | +21.5% |
| May 4, 2026 | -5.2% | +10.3% | +15.3% |
Sales grew every year from 2023 to 2025, to $603M. It made a profit in each of the three years.
RSI 45.6, MACD below signal, below its 50-day, above its 200-day. Not scored.
5 insiders sold $12.9M across 15 filings in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: UFPT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
“The medical design and contract manufacturing industry is highly competitive as is the foam and plastics converting industry as a whole.”
UFPT scores 5 today, which Breakaway calls Below Average. It is #30 of 86 in Medical Devices by Quality Score, with 2 of 14 chart checks firing. Up 18% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and medical device stocks a median 7%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
UFPT scores 5 today, which Breakaway calls Below Average (0 to 5). That is #30 of 86 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind UFPT's 5.
5 insiders sold $12.9M across 15 filings in the last 6 months. No open-market buys on record. The newest is Marc D. Kozin, Director, who sold $1.1M on Aug 25. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.